Fundraising Fox
Gisens Biotech
Techstars '24Berkeley, US · Founded 2020 · 13 employees on LinkedIn · 2 known investors
Find your way into Gisens Biotech
Sign up to see every warm intro you have to Gisens Biotech
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Gisens Biotech team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Gisens Biotech develops G-LoC, a portable graphene-based biochip technology that delivers rapid health monitoring and diagnostic test results from home samples in minutes rather than days. The company's initial product, KF4+, is designed for patients with chronic kidney disease to perform comprehensive kidney function testing at home with results integrated into electronic health records.
Also known as Gisens
Investors · 2
How we know: GRIDX's portfolio page · a partner's Signal profile · Not right? Tell us
How we know: the Techstars portfolio · open dataset · Top 3000 Accelerator Startups (no YC) 2026-08 · Not right? Tell us
Company profile
researched Sep 2026Gisens Biotech is a biotechnology company developing portable diagnostic technology for personalized medicine, based on nanotechnology. Its core platform, G-LoC, is presented as a portable technology able to analyze a patient sample — for example saliva — at the patient's home and return quantitative results in minutes, with a stated accuracy of over 95.5%. The company frames the problem it addresses as the dependence of most testing on centralized laboratories, which requires either patient travel or sample shipping and introduces delays, access limitations and potential loss of sample accuracy.
The company's first application is KF4+, a device powered by G-LoC that performs a comprehensive kidney function test for patients with chronic kidney disease (CKD). KF4+ is described as measuring key biomarkers including urea, sodium, potassium, chloride and creatinine, with results delivered in minutes and integrated directly into the patient's electronic health record to remove lab visits and reduce data fragmentation. Gisens cites the scale of CKD in the United States — more than 5 million people affected and tens of thousands of new diagnoses each year — as the rationale for this initial focus.
Traction
Gisens Biotech is listed among Berkeley SkyDeck companies and appears in the Berkeley Startup Cluster directory, which describes it as having developed a saliva test allowing patients with kidney disease to monitor their health.
Latest developments
The company is presenting KF4+, its G-LoC-powered kidney function testing device for patients with chronic kidney disease, as its lead product, with results designed to flow into electronic health records.
▸Full profile — market position, technology, go-to-market, geography
Market position
Positions G-LoC as the first portable technology to deliver real-time results from any location and KF4+ as the first device to deliver a comprehensive kidney function test in minutes rather than days, in contrast to centralized laboratory testing workflows.
The stated differentiators are point-of-need testing without sample logistics or shipping, results in minutes instead of days, a multi-analyte kidney panel from a home-collected sample, quantitative output with accuracy above 95.5%, and automatic integration of results into electronic health records.
Technology
G-LoC is a portable testing platform that analyzes patient samples, including saliva, outside of a laboratory setting and returns quantitative results in minutes at a stated accuracy above 95.5%. The company describes its diagnostics as powered by nanotechnology. The KF4+ device built on G-LoC measures multiple kidney-function biomarkers — urea, sodium, potassium, chloride and creatinine — in a single test and transmits results into the patient's electronic health record.
Go-to-market
Patients requiring frequent health monitoring who currently depend on centralized laboratories, with an initial focus on people with chronic kidney disease in the United States. The company also references use by physicians personalizing treatment and by home care providers who need rapid results.
Geography
Headquarters and US office at 2150 Shattuck Avenue, Berkeley, California, with laboratory facilities in Latin America at 295 Diagonal 113, La Plata, Buenos Aires, Argentina.
Compiled by commissioned research from 5 cited public sources — announcements, filings, and press listed under research sources below.
Key figures
latest reportedCompany-reported or press-reported figures, each dated to when it was claimed — not independently audited.
Related companies · 1
Companies working in the same space as Gisens Biotech.
Timeline · 1
launches, deals, and filingsGisens Biotech appears in Berkeley SkyDeck's company listing, dated 5 February 2024.
Dated company events from announcements, filings, and press; legal rows summarize public dockets and regulator releases.
▸Research sources · 5
primary sources listed
- Gisens Biotechgisensbiotech.com · web
5 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does Gisens Biotech do?
- Gisens Biotech builds G-LoC, a portable biochip platform for at-home diagnostic testing, starting with kidney function.
- Who are Gisens Biotech's investors?
- Gisens Biotech's investors include GRIDX, Techstars.
- Where is Gisens Biotech headquartered?
- Gisens Biotech is headquartered in Berkeley, US.